Early-stage venture · Los Angeles, California
Early-stage capital for breakthrough deeptech.
EGB Capital invests in early-stage companies commercializing breakthrough science across engineered biology, novel chemistries, and other defensible deeptech sectors.
Early-stage investment across biology, therapeutics and deeptech
EGB Capital is an early-stage venture capital firm based in Los Angeles. We invest in transformative, technically defensible companies developing breakthrough scientific and engineering innovation.
We partner with deeply technical, mission-driven founders at the earliest stages to help shape commercialization, partnership, and patient impact to build toward durable long-term value.
What we invest in
We primarily invest at pre-seed and seed, with selective participation in Series A, across the United States and Europe.
Therapeutic plaforms
Synthetic biology
Biomanufacturing
Cell and gene therapy infrastructure
Novel chemistries
Advanced materials
Computational biology
Enabling deeptech platforms
Our thesis
We believe some of the most important companies of the next decade will come from overlooked technical breakthroughs rather than crowded hype cycles.
We are especially drawn to companies with strong technical differentiation, defensible intellectual property, clear unmet market need, and the potential to unlock entirely new capabilities across large markets.
- 01Critical unsolved problems
- 02Overlooked but important parts of the value chain
- 03Platform and enabling technologies
- 04Strong technical moats
- 05Deeply technical, mission-driven founders
- 06Commercial pathways grounded in real-world value
Portfolio
We invest in companies pursuing technically ambitious work with the potential to create real commercial and industrial impact.
CellFE
Microfluidics-based platform for cell therapy manufacturing.
Syntax Bio
Synthetic biology platform facilitating pre-programmed sequential CRISPR activations for cell differentiation.
Izote Biosciences
Bioproduction platform utilizing anaerobic respiration.
DesiCorp
Technology for freeze-drying human red blood cells for transport and long-term storage.
SoFab
Low-cost, high-performance electron transport layers.
Kebotix
Materials discovery and chemical optimization.
MiLaboratories
Computational biology platform for next-generation therapeutic development.
Circe
Carbon-negative manufacturing of essential fats.
Sironix Renewables
Bio-based, non-carcinogenic anionic surfactants.
Fork & Good
Cellular engineering platform for cultivated pork and beef cells without growth factors.
Dinya DNA
Synthetic biology platform producing ultra-long DNA sequences with high fidelity and low cost.
Enrich Biosystems
3D-printed hydrogel microwells for high-throughput co-culture cell screening.
Swan Genomics
Low-cost genomic sequencing using plasmonic nanoantennae and DNA origami.
RiboForge
Technology for deriving 3D structures of mRNA and pre-mRNA.
Biotia
Pathogen sequencing platform for biosecurity and diagnostics.
Extellis
Metamaterial technology designed to reduce the cost of mSAR satellite imagery.
Sift Biosciences
Molecular mimics designed to turn cold tumors into immune targets.
Heritable Agriculture
Making plants programmable.
Team
Douglas Munsey is an entrepreneur, investor, and healthcare operator focused on identifying compelling early-stage deeptech opportunities and supporting portfolio companies as they grow.
Prior to founding EGB Capital, Douglas helped launch the Olympus Innovation Fund at Touchdown Ventures. He began his investment career as an analyst at Morgan Stanley covering the medical technology sector.
Earlier in his career, Douglas was one of the first employees at medical device manufacturer Ki Mobility, where he held a range of operating roles spanning purchasing, logistics, and data analysis. He helped the company scale to more than $60 million in revenue and supported its sale to ETAC.
Douglas was also a co-founder of Syntax Bio, a synthetic biology platform focused on precision cell differentiation. The company has raised capital from prominent biotech investors and secured a development partnership with Astellas Pharmaceuticals.
As an angel investor, Douglas has made more than a dozen investments in early-stage companies.
He holds a B.B.A. from the University of Wisconsin–Madison, and both an M.P.H. and M.B.A. from the University of California, Berkeley.
Luke Riggan is an immunologist and biotech founder.
He founded ImmunoVec, a gene and cell therapy spinout from UCLA, giving him first-hand experience taking a technology out of an academic lab and building a company around it.
At EGB Capital, Luke advises on scientific diligence across therapeutics, cell engineering, and enabling biology platforms, helping assess the technical foundations behind early-stage opportunities.
He holds a Ph.D. from the University of California, Los Angeles.
What founders say
“Doug gives useful and pointed strategic advice without being overbearing. He is particularly capable at translating technical capabilities into viable commercial approaches.”
“Douglas has supported CellFE from the beginning and believed in us before anyone else. His advice and support have been instrumental in getting the company to where it is today.”
“Doug has always had Syntax’s best interests in mind. Through thick and thin, he has been there when very few investors, or none, have been there for the company.”
Get in touch
Whether you’re a founder building in deeptech or an investor interested in learning more about EGB Capital, we’d be glad to hear from you.
contact
Los Angeles, California
